PCN71 Treatment-Related Costs of Pharmacologic Regimens for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Who Have Received Two or More Prior Lines of Therapies

Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.163
https://www.valueinhealthjournal.com/article/S1098-3015(21)00380-6/fulltext
Section Title :
Section Order : 10741
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00380-6&doi=10.1016/j.jval.2021.04.163
HEOR Topics :
Tags :
Regions :